Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Resubmission Acknowledgement Letter Class 2 - Intersol

Our STN: BN 080041/0

Fenwal, Inc.
Attention: Mr. Matthew Nowland
Three Corporate Drive
Lake Zurich, IL 60047


Dear Mr. Nowland:

We received your June 11, 2009, resubmission to your new drug application (NDA) for InterSol Solution on June 12, 2009.

The resubmission contains additional CMC, clinical, statistics, toxicology/leachables materials, and compliance information that you submitted in response to our April 6, 2009, complete response letter.

We consider this a complete, class 2 response to our action letter. Therefore, the user fee goal date is December 12, 2009.

If you have any questions, please contact the Regulatory Project Manager, Heather Erdman, at (301) 827-6182.


Sincerely yours,



Basil Golding, M.D.
Division of Hematology
Office of Blood Research and Review
Center for Biologics
Evaluation and Research

Page Last Updated: 09/25/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English